A Study in Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1369 participants.

Also called NCT01468987

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,369 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01468987
  • EudraCT 2011-001254-29
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Brazil, Croatia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01468987. Randomized; quadruple masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-08 (actual). Results posted on 2018-04-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Participants With Type 2 Diabetes Mellitus
Acronym
IMAGINE 4
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2605541
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Insulin Lispro
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01468987
Content hash
200bc69c624bf3da218eaa16af85011bac5a01d37162d5d8145da7f67a76e770